BPC-157 is a peptide that has shown promise in promoting healing and reducing inflammation in animal studies
Factors such as food interactions and bioavailability will be different for individuals across a patient population with a broad mix of physical and genetic characteristics
In my experience, people who take GLP-1 therapies fall into several categories
Physical symptoms may include weakness, pale or yellowish skin, numbness or tingling in extremities, balance difficulties, mood changes including depression or irritability, and tongue inflammation
Notably, these populations also exhibit lower levels of L-carnitine in their tissues compared to less-vulnerable healthy populations 4
NKT cells are divided into two major subsets: type I NKT cells (the majority, with conserved T cell receptor (TCR) V24-J18, recognizing CD1d-presented glycolipid antigens like -GalCer) and type II NKT cells (with diverse TCRs, recognizing self-lipid antigens, such as Lyso-GM1) (105)